List of exhibitors

5.9 S.r.l. is an Italian leading company of weighing systems for medical applications. Monitoring the patient’s weight during invasive medical treatments, such as dialysis, allows the medical staff to verify the patient’s health conditions just in a glance. We developed an integrated weighing system with touch display, able to create a dedicated patient file, complete with the treatment information and the patient medical history.
Our product range includes bed scales and armchair scales, and also dedicated and customizable weighing systems in accordance with any customer need.
Moreover, we recently developed a brand-new mobile weighing system that can be added and adapted to any medical furniture already in usage in hospitals.

A UNO TEC designs and realizes customized automatic machines for the assembly of medical devices, in plastic materials for clean rooms. Specializing in Infusion Therapy and Dialysis, it constitutes a benchmark in the development of solutions for the assembly of medical products required by the manufacturing medical market. The wide variety of clients, spread across the world, has contributed to enrich its technical knowledge and innovating capability, ensuring an efficient turnkey service.

Creation of French-made healthcare equipment.

We are an innovative and dynamic French company, we create solutions for various hospital services.

Aferetica is an innovative SME, founded by managers with thirty years’ experience in blood purification who wanted to leverage their competence in purification therapies and the know-how in biomedical technologies in order to apply aphaeresis techniques in new fields, such as organ management for transplantation.
Aferetica’s mission is to drive and incentive the creation of a network, which must be able to create, validate and use aphaeresis therapies in clinical practice, initiating their use in new clinical areas.
Aferetica wants to meet current transplantation needs, transforming organ preservation in organ recovering and regeneration, through the combination of Aphaeresis and perfusion techniques.
This mission leads to the design and the development of integrated systems for organ ex vivo management, such as PerLife, with:
• Machines
• Disposables
• Solutions
• Dedicated Sorbents.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Allmed is a vertically integrated global manufacturer, selling and operating in over 40 countries around the world.
Allmed has a wide product range in the haemodialysis consumables market space, and is home to multiple patented and innovative products, including:
– The market’s only steam-autoclaved Polysulfone dialyzer range
– A special therapy BIOREMA® 26H high-capacity filtration product line, as well as
– The BIOCARB-G: a bicarbonate cartridge whose patented design allows it to enjoy the lowest carbon footprint of any comparable product on the market.

We are committed to offering customised solutions to Haemodialysis professionals and patients in.

Alnylam is leading the translation of RNA interference into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious and central nervous system and ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for treating a wide range of severe, debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.

Alnylam has funded the scientific medical educational part of the meeting only.

Aqua Biotech srl is a company that operates in the field of Research and Development,
dissemination of techniques and products useful in the medical and clinical-surgical sector.
In particular, the company has as its priority the implementation of clinical protocols and the
design and implementation of innovative devices and compact and portable electronic
systems for medical applications and biological signal monitoring.
Aqua Biotech srl uses a highly qualified and integrated structure, consisting of:
Health Department, Operations Department, Operations Centre, ICT Systems, Teams of
Medical Specialists and Health Professionals.
The Area of Training and Communication is an organ of the Staff in the Health Department,
together with which it plans and controls the assistance activities and continuing training of
the personnel that constitute the operational center and the health team.
Within the organization there is a Operations Center with experienced operators coordinated
by the operational management, which operates on an integrated platform with the
telephone exchange and telemedicine systems.

Aqua Biotech srl è una società che opera nel campo della Ricerca e Sviluppo, diffusione di tecniche e prodotti utili nel settore medico e clinico-chirurgico.
In particolare, l’azienda ha come obiettivo prioritario l’implementazione di protocolli clinici e la progettazione e implementazione di device innovativi e di sistemi elettronici compatti e portatili per applicazioni medicali e di monitoraggio di segnali biologici.

Aqua Biotech srl si avvale di una struttura altamente qualificata ed integrata, costituita da:
Direzione Sanitaria, Direzione Operativa, Centrale Operativa, Sistemi ICT, Equipe di Medici Specialisti ed Operatori Sanitari.
È organo in Staff alla Direzione Sanitaria l’Area della Formazione e della Comunicazione insieme alla quale pianifica e controlla le attività assistenziali e di formazione continua del personale che costituisce la centrale operativa e l’equipe sanitaria.
All’interno dell’organizzazione è presente una Centrale Operativa con operatori di esperienza pluriennale coordinati dalla direzione operativa, opera su una piattaforma integrata con il centralino telefonico e con i sistemi di telemedicina.

In Asahi Kasei’s medical enterprises, we have developed new medical devices and therapeutic technologies and made advances in biopharmaceutical and plasma derivative process engineering. We have achieved these through a high-level synergy of filtration and separation technologies using membranes, filters and adsorbents, together with wide-ranging knowledge and technological expertise in science, mechanical engineering and medical fields. Our filtration and separation technologies for blood and body fluids hold great promise as core technologies for integrative innovation.

The rapid evolution of technology and life sciences has brought new opportunities for scientists to develop ground-breaking research and make discoveries that improve and save people’s lives.

Astellas is working on the forefront of this healthcare change, combining our powerful mix of expertise, radical new science and technology with a relentless challenger spirit.

We are unusual in our ability to combine the experience, expertise and resources of an established company with the agility, flexibility and tenacity of a start-up. Relentless curiosity and a hunger for discovery flows throughout our entire organisation and is embedded in everything we do.

We take a patient-focused approach, that allows us to convert brilliant early science into treatments and solutions that directly improve and save patients’ lives. From lab to clinic to patient, we focus on the most promising science, empower the best talent to pursue it, and develop life-changing solutions alongside the best partners.

We pursue innovative science, focussing initially on the areas of greatest potential and then developing solutions where patient need is high, often in rare or under-served disease areas and in life-threatening or life-limiting diseases and conditions.

Delivering meaningful differences for patients is the driving force behind our EST-C team. We actively nurture an open and progressive culture, working with partners who share our passion to make a meaningful difference to the people who need it, by delivering treatments of value with the potential to improve health and redefine care.

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas , AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities.

As one of the world’s leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun’s success today—always with the goal of improving clinical outcomes, cost of care and patient benefits.

More than 66,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2021, the B. Braun Group generated sales of € 7.9 billion.

Bain Medical Equipment (Guangzhou) Co., Ltd., was established in 2003, is a leading manufacturer of medical equipment (consumables) for blood purification/hemodialysis treatment.

Headquartered in Huangpu District, Guangzhou. The Group Company has subsidiaries in Hong Kong, Taiwan, Turkey,Pakistan and India ect, with more than 3,000 employees worldwide.

The company is committed to the Research and Development, Manufacturing , Sales of device and disposables for blood purification. At present, the main products are Hollow Fiber Hemodialyzer, Tubing Sets for Hemodialysis, Disposable A.V. Fistula Needle Sets, Hemodialysis Machine, Disaposable Dialysis Care Kits, etc.

Aiming to be the best manufacturer in China , one of the top three worldwide in the field of blood purification, Bain Medical global sales network have been covered more than 80 countries and regions in Europe, Asia, the Middle East, Latin America, Africa and South America, The company is keeping moving ahead to a higher and stronger position, adhering to a quality policy of “Quality means a lot to life; Quality makes great achievement”and the purpose of ‘serving the people, contributing to the society’ and independent innovation.

Uniting to Save and Sustain Lives
Driven by Our Purpose, Destined to Transform
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. Everything we do converges at the critical intersection where products that save and sustain lives meet the healthcare professionals and caregivers who make it all happen.

With products, therapies and digital solutions available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

www.baxter.com
https://www.linkedin.com/company/baxter-healthcare/
https://twitter.com/baxter_intl?

Bayer is a life science company and a global leader in healthcare and nutrition. Our innovative products support efforts to overcome the major challenges presented by a growing and aging global population. For more information, go to www.bayer.com

Bio Preventive Medicine Corp. (BPM), a leading company in renal biomarker area, focuses on translating clinically validated and IP-protected (>79 patents) biomarkers into precision diagnostic solutions for unmet clinical needs. The disease area we focus on includes diabetic kidney disease (DKD), renal injury, and oncology.

Human uPTM3-DKD (DNlite-IVD103) ELISA test is a urinary prognosis test for predicting/monitoring risk of kidney disease progression, and it is perfect for routine clinical practice in any healthcare institutes and clinical labs. Besides precision management of DKD, it can also be applied for risk assessment of Acute Kidney Disease, and Graft Failure in kidney transplant patients.
Commercially, DNlite-IVD103 is CE-IVD marked, approved by Malaysia MDA, and also launched in Japan and US as RUO kit. Furthermore, several other worldwide regulatory approvals are in preparation.

Bionic Medizintechnik GmbH is located in Friedrichsdorf near Frankfurt/Main, Germany. We specialised for products in vascular access, therapy chairs and transfusion for more than 30 years. As a member of the JMS group we are the headquarter for all activities in Europe.

You are viewing an international congress run by the European Renal Association (ERA) and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of the ERA, best efforts were undertaken by ERA and congress sponsors to ensure compliance with the EFPIA code of practice, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.
The materials for empagliflozin contained in this virtual exhibition are approved for use only in countries regulated by the European Medicines Agency (EMA). Prescribing information may vary depending on local approval in each country inside and outside of Europe. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

About Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need. Clinical trials have been initiated to evaluate the impact of empagliflozin on people living with heart failure or chronic kidney disease.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.”

After 85 years of experience, Chiesi Group, a family-owned and run certified B Corporation company, launched Chiesi Global Rare Diseases in 2020.
Chiesi Global Rare Diseases is focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care.
Chiesi is the largest pharmaceutical group in the world to be awarded B Corp Certification.
B Corps are businesses that balance purpose with profit. They are legally required to consider the impact of their decisions on their workers, customers, suppliers, community, and the environment. This is a global movement of people using business as a force for good.

Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. Chinook’s
product candidates, including atrasentan, BION‐1301 and CHK‐336, and research & discovery programs, are being
investigated in rare, severe chronic kidney disorders with opportunities for well‐defined clinical pathways. To learn
more, visit www.chinooktx.com.

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries
For more information about CSL Vifor, visit CSLVifor.com.

CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate systemic inflammation – with the goal of preventing or treating multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. CytoSorb® is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. More than 195,000 individual applications have been performed worldwide. Learn more at cytosorb.com.

Based in Switzerland, Dialife is a global provider of high quality products, equipment and services for renal care. We offer a comprehensive range of devices and products for hemodialysis treatment, including dialysis machines, dialyzers, tubing sets, fistula needles, sodium bicarbonate cartridges, concentrates, disinfectants, endotoxin filters, on/off kits and more. We also provide turnkey solutions to set up dialysis clinics, as well as transfer technology services for the production of dialysis products.

At Dr. Schär, we have been working for 100 years to improve the lives of people with special nutritional needs. Flavis is the line of protein-free foods, created to satisfy the nutritional needs of patients with chronic kidney disease who follow a low protein diet. Flavis offers a wide range of tasty and convenient products with a balanced nutritional profile (low in sodium, phosphorus and potassium, rich in fiber). They are also an important source of energy to effectively prevent protein-energy wasting. With protein-free bread, pasta and biscuits, but also snacks and ready meals traditional products can be easily replaced. Consequently, adhering to dietary recommendations is much easier.

Since 30 years, DWA has specialized in innovative solutions for the supply of high purity water to dialysis centers – worldwide. DWA develops systems for the production of ultrapure permeate and its distribution right to the dialysis machine. Our expertise in water treatment covers all aspects from the pre-treatment stages, through reverse osmosis, ultrafiltration and heat-disinfection systems, right up to the supply connection through to the dialysis machine. In addition, DWA offers systems for the distribution of acid and bicarbonate concentrates. Since its inception, DWA has been setting standards in dialysis water treatment and is the only company producing ultra-clean permeate by the combination of reverse osmosis and central ultrafiltration, including integrated simultaneous heat-disinfection of the ring mains to the dialysis machines. DWA is your global partner for the design, planning, installation, extension or conversion of dialysis centers and offers project management, installation and commissioning as well as service and maintenance from a single dedicated source.

Emodial develops advanced solutions for the vascular access management in dialysis: the Silver line of pads, plasters and pockets for CVCs, peritoneal catheters and PICCs releasing silver ions with antibacterial and anti-inflammatory action, also available in procedural kits for start/end treatment and, upon completion of advanced dressings, the innovative waterproof pockets for catheter, for bath and shower.

Founded in 1980, the company offers its over 40 years of acquired experience to the market.

The quality, the offered service, as well as the orientation towards the customer and above all, towards the patient, has allowed and allows to maintain cooperations with the most important international players.

The range of products from the most standard to the most customized ones covers a large number of configurations for dialysis, infusion, oncology and nuclear medicine treatments.
The recorded growth, particularly in the last 15 years, has led EffeEmme to build connections and to participate in foreign companies contributing to realize production facilities in Tunisia and Romania; facilities which follow the sector’s best practices.

Fluid-o-Tech group is a leading supplier of technology to move, dose and sense fluid such as volumetric pumps, electronic valves, sensors and fluid systems in health technology field.

Fluid-o-Tech S.r.l is an Italian leading company with over seventy years of experience in the design and manufacture of positive displacement pumps and fluidics systems for accurately dosing and controlling fluids, for the medical, food service, automotive and many other mission critical fields.
The company with over 300 people worldwide and a direct presence in Italy, Germany, UK, USA, China, Japan and more than 120 distributors in over 60 countries, exports +80% of its production. Its factory is considered a model example for Industry 4.0. Quality and Innovation are the company strategic pillars, 5% of revenues are invested yearly in R&D involving 16% of its staff.
Fluid-o-Tech is a leading global supplier of fluidic solutions for the medical sector. It is committed to develop with its partners enabling technologies for medical devices to give access and improve therapies quality especially in the field of Health Tech.
Fluid-o-Tech positive displacement gear and peristaltic pumps are able to deliver precision flow. The gear pump range offers an impressive turn-down ratio and high pressure capability to meet your flushing and analytical needs.

In 2014, Dolphin Fluidics was born as an innovative startup within the Fluid-o-Tech Group by synergistically combining the Fluid-o-Tech Group’s experience in the precision fluid dynamics field with co-founder, Francesco Butera, 20 plus years of experience in the field of smart actuators based on shape memory alloys. Dolphin Fluidics is established with a specific pursuit: “to do what others do not do.” This iniative translate into the fluidics world with our primary mission being that “we digitalize fluidics,” meaning we develop and produce digital systems for precise fluid control and dosing based on the integration of precision fluidics, shape memory smart actuators and digital control electronics. We provide intelligent digital valves to mix, dose and detect fluids, combining embedded electronics, connectivity and smart actuators, enabling a new user experience and customer value through data.
Dolphin Fluidics and its team of outstanding engineers support each project from concept to production, integrating their expertise into customer applications.

Founded in 2013, F-Lab is an innovation center where highly qualified engineers and designers work together with universities, companies and experts on new technologies and materials to explore and develop ingenious solutions.
F-Lab aspires to be a model for future enterprising, in which people work together without hierarchies taking advantage of networking and new technologies to accelerate the innovation process.

We can offer technical solutions for those devices where hydraulic parameters are critical for safety and performance requirements. In the dialysis machines, the complex process of fresh dialysate continuous generation requires high quality standards. Fluid-o-Tech pumps, valves, and sensors are key to precisely manage fluids within the dialysis systems.
We are the ideal partner to develop fluidic solutions with our Customers for use in medical devices.
Thanks to our experience, know-how, commitment and passion we bring patients hope for a better future.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,116 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical has been a leading, global clinical research organization for more than 20 years. With over 450 experienced people in 19 locations able to manage clinical trials in up to 70 geographies throughout the Asia-Pacific region, USA and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all phases, registration and post-marketing trials.

GSK is a global healthcare company that unites science, technology and talent to get ahead of disease together. We are committed to unlocking the science of renal disease, for healthcare professionals managing it and for people impacted by it. We will be sharing, and discussing the latest science and emerging evidence around kidney outcomes at ERA 2023, so please visit us at our booth [booth number] and attend our industry symposia educational sessions to learn more about GSK in nephrology.

Visit GSK at ERA 2023. Ahead Together in Nephrology.

BIOLIGHT was IPO since 2011 and is currently trading in the SHENZHEN STOCK EXCHANGE. Founded in 1993, BIOLIGHT is an internationally established leading provider in medical devices, medical consumables, and healthcare solutions. Including patient monitoring, emergency responds, hemodialysis renal care, and digital health homecare solutions.
BIOLIGHT, with headquarter in Zhuhai China, has a firm global RND, Marketing, Sales and Service presents. Biolight has established 8 researches and manufacturing plants, 12 subsidiaries, and oversea sales branches covering sales and services in Asia, Africa, Europe, North America, and Latin America expanding over 135 countries and counting. We established 7 high-techs manufacturing campus across China, located in Zhuhai, Tianjin, Liaoning, Chongqing, Changzhou, and Nanchang, with a combine area of 1,898,000 sqm conveniently and efficiently deliver quality products across the country and across the global.
BIOLIGHT maintains many long-term relationships with top universities, global health
organizations, health and social responsibility organizations actively involves in educations,
humanitarian mission, and patient care social projects. Fulfilling corporate social responsibility is
one of our core missions at BIOLIGHT. As an integral part of global economic ecosystem,
BIOLIGHT has made constant effort to contribute to public welfare in China and across, focusing largely in: access to education, access to technology, public health, and sustaining communities.
BIOLIGHT will continue to maximize the impact of our corporate responsibility programs by leveraging our unique company resource in biomedical engineering and digital health creating a platform to better focusing on generating values for our society.

About Hansa Biopharma
Hansa Biopharma is a pioneering biopharmaceutical company and our mission is to develop innovative, lifesaving and life-changing treatments for patients with rare immunological conditions. Hansa has developed a first-in-class Immunoglobulin-G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitised patients. Hansa has a rich and expanding research and development program exploring a broad range of conditions. Our pipeline is focused on advancing the Company’s proprietary enzyme technology to develop the next generation of IgG-cleaving enzymes to enable repeat dosing in relapsing autoimmune diseases, chronic transplant rejection, oncology and gene therapy.

Find out more at https://hansabiopharma.com.
Address: Scheelevägen 22, 223 63 Lund, Sweden
Phone: 046-16 56 70

ICU Medical is global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology. Our robust portfolio features products for medication delivery, vital care, monitoring, and patient safety that help provide precision, accuracy, and reliability across the continuum of care.

InBody is one of the worldwide leaders in body composition technology.

Non-invasive, fast and with little effort, InBody provides a comprehensive overview of a person’s overall health. Through data such as body fat mass, segmental muscle mass, body water and body mineral content, the result sheet provides a profound basis for the formulation of training and nutrition plans.

Furthermore, our digital solutions offer data transfer to the InBody CLOUD and InBody APP.

For more information, visit nl.inbody.com and get to know our life concept on site and take a measurement at our booth.

Infomed, worldwide player on blood purification devices offers complete solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Active since more than 25 years, Infomed continuously innovates to create devices designed to reach your topmost needs. Dimi, our homecare dialysis device, is the partner for a new life at home. Dimi was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements thanks to various therapies available such as peritoneal dialysis and hemodialysis.
Our products are adapted for adult, child and babies. We work for human well-being thanks to a large range of treatments available on our devices which include the “all in one” philosophy, as Infomed, we focus on you!

Werfen is a worldwide leader in specialized diagnostics in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity. Through our OEM business line, we research, develop and manufacture customized assays and biomaterials. Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. At present, we operate directly in nearly 30 countries and in more than 100 territories through distributors. Our R&D and production centers are located in the United States and Europe. Every day, hospitals and laboratories around the world use our reagents and systems to test 1.8 million patient samples. Glycated Albumin (GA) is an important part of the Werfen Clinical Chemistry portfolio. GA is a mid-term glycaemic marker. It is a unique marker capable to address and evaluate glycaemic status in DKD patients, highlighting therapy adherence and success or changes in glycaemic profiles.

Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry. With a market value of $7 billion, Jafron has three branches, 11 subsidiaries, one sub-subsidiary and medical foundation, insurance, etc.

Jafron has diligently devoted to the R&D, production and sales of blood purification products primarily in the hemoadsorption field for decades. It is dedicated to providing professional services to patients worldwide, covering ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, etc.

Jiangsu Solicitude Medical Technology Co., Ltd. (SMT Group) is a high-tech enterprise which focuses on the field of blood purification and biopharmaceutical. It has the strength of R&D, producing spinning systems, assembly systems, manufacturing finished products and selling a full range of filters, especially hollow fiber membrane, hollow fiber hemodialyzer and tangential flow filters.

Jiangxi Sanxin Medical Technology Co., LTD was founded in 1997. It’s a national high-tech enterprise specializing in the research and development, manufacturing, sales, and service of medical devices.

Relying on the company’s advanced scientific and technological innovation platform, the company has excellent capability to transform scientific and technological achievements. At present, the company’s products cover five series: “blood purification, injection, indwelling catheter, transfusion, and cardiothoracic surgery. As a top 3 hemodialysis consumable exporter in China, Sanxin Medtec can provide a one-stop solution service for consumables and equipment.

JIHUA Medical Apparatus & Instruments Co., Ltd GUANGZHOU, established in 2000, currently located in Tianhong Technology Park, is the corporate enterprise win-win combined by Landwind Group. It is State key high and new technology enterprise by researching, developing, producing, selling, service and dialysis operations center for blood purify device and consumables.

Confirmed by ISO 13485, ISO 9001 and CE, JIHUA company occupy about 3000 square meters for production site and more than 60 experienced experts and technicians focusing on the production, R&D and services. So far, JIHUA products has been exported to more than 60 countries in Europe, Asia, South America and Africa countries. JIHUA company is guiding Chinese hemodialysis to overseas market.

Joline is an internationally active medical device company located in the South of Germany with more than 20 years experience in minimally invasive therapies. Joline is an expert provider of catheter, balloon and stent technology for various medical applications and maintains an important tradition of “Made in Germany” quality in all its products and services. All Joline products are developed and produced exclusively in Germany. We integrate quality aspects in our daily work and strive to meet the high standards of our customers. The highest priority we place on the health and safety of our patients.

KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves.

Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999. Lepu Medical is specialized indeveloping, manufacturing, and distributing high-tech medical devices and equipment. Today, LepuMedical has grown into a global leading group company in the fields of cardiovascular, neurovascuar, and peripheral vascular interventions, structural heart diseases, surgical cardiology, cardiacrhythm management, anesthesia, and critical care, in vitro diagnostics and general surgery.
OCI Medical was founded in 2005 and became a subsidiary of Lepu Medical in 2012. lt is a high-techenterprise specializing in the R&D, production and sales of blood purification products. lts independently developed and produced PES hollow fiber membrane hemodialyzer has been widelyused in thousands of hospitals and dialysis centers, covering most hospitals in China, and exportedto dozens of countries overseas.

LiKAMED is a globally leading manufacturer of therapy chairs. Our products combine safety, quality, patient comfort, longevity and cost efficiency with design and more than 40 years of experience. In addition to a wide range of products, we also offer service and technical expertise to cover every needs of our customers all over the world.

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOS™ CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.

Beyond the THERAKOS™ CELLEX™ Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients.  Therakos have been crafting ECP solutions (products, services and education) since 1987.

To learn more about this product visit www.therakos.eu

Fluid management in hemodialysis and PD patients is at best challenging. Having the right tools can result in better management of patients, reduce staffing time and help with cost saving.

Maltron will showcase the BioScan touch i8 the most advanced Bioelectrical Impedance Body composition Monitor in its field. The first system, calibrated for Adults and infants. Accurate assessment of full body and direct segmental compartments are important to better understand the changes underway in these patients. Correct quantification of Dry weight, Malnutrition, loss of Muscle Mass, Excess Fluid, Intracellular, and Extracellular are some of the important parameters in patient care which are available in the touch i8.

The uniqueness of the BioScan provides you with the ability to perform comprehensive screening of different parameters. With Maltron’s patented technology used in the BioScan touch i8 you are able to monitor and track changes in both cellular and in Intravascular, Extravascular and Interstitial compartments giving you a complete understanding of the fluid shifts and the associated risks to the patient.

Come visit us at stand F.510 and learn more about our approach to better manage patient care.

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines.

Our 427 diverse and open access journals, including 418 peer-reviewed journals and 9 conference journals, are supported by more than 115,000 academic experts who share our mission, values, and commitment to providing high-quality service for our authors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).

MDPI publishes over 98 journals that are ranked as high impact within their fields. To view the current impact factors for MDPI journals (according to the Journal Citation Reports), please visit our yearly announcement page here: https://www.mdpi.com/about/announcements/4095.

MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function.

The Company recently conducted the TGFR Pivotal study (NCT05425719). The TGFR Pivotal study is a Phase 3 open label, multi-center, safety and pharmacokinetic study of Lumitrace® (relmapirazin) and the use of the MediBeacon Transdermal GFR Measurement System (TGFR) in normal and renal compromised subjects for the evaluation of kidney function.

In preclinical research the MediBeacon transdermal GFR system tracks Glomerular Filtration Rate (GFR) without restraining the animal. The system obviates the need for blood sampling, urine collection, and laboratory assays thus enabling superior trial design. The result is enhanced kidney therapeutic assessment, nephrotoxicity evaluation and fundamental understanding of kidney function in animals. For more information, please visit: www.medibeacon.com

Medica Group is a leading manufacturer of medical and water purification device operating since 1985 in the biomedical district of Mirandola in Italy.
BUSINESS UNITS:
– Medical Division: disposable and equipment for blood purification, cardiology, organ transplant, bioregenerative medicine,
urology, gastroenterology and oncology.
– Water Division : ultrafiltration and microfiltration from home drinking to hospital and pharma applications.
– Automation: assembly equipment for medical device manufacturers.
STRENGTHS:
– Vertical integration from R&D to manufacturing for disposable, medical equipment and assembly technology.
– Know how integration makes Medica Group a strategic partner and a global solution provider for many multinational
corporation.
– Hollow fiber spinning technology for blood and water purification.

Medcomp will be in attendance at this year’s ERA showcasing our wide range of hemodialysis products! Did you know that Medcomp® develops, manufactures, markets, and supports cutting-edge vascular access devices and accessories to meet the clinical needs of the medical industry, particularly in the fields of interventional medicine and dialysis? Our company’s engineering and applications expertise provides superior products whose progressive designs accommodate advances in medicine and whose quality anticipates the requirements of our professional clients and the patients they serve. Stop by our booth to see in-person what products we have to offer!

MEDIKIT is a leading Japanese manufacturer of medical devices for vascular access such as plastic fistula cannula and intravenous catheter along with interventional instruments. In 2023 MEDIKIT is celebrating its 50th anniversary. With this long experience, we support hospitals and healthcare services around the world as a strong and reliable technology and service partner. MEDIKIT develops innovative products – like our dialysis cannula with full cover safety mechanism – with a high commitment to quality, and thus intends to contribute to the improvement of treatments and future medical technologies. Our mission is to reduce the burden on patients during the treatment and at the same time improve safety for medical staff. In this way, we want to be of help to the well-being of the societies in which we live.

Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

Our goals:

To achieve the most rigorous and practical education using various platforms
To provide education that focuses on a therapeutic area within the context of the continuum of patient care
To help physicians fulfill their commitment to lifelong professional development
To help improve patient care

MedXL manufactures a diverse line of prefilled syringes including sterile water syringes, normal saline syringes and anticoagulant prefilled syringes such as sodium citrate and saline. Prefilled syringes help to improve healthcare professionals’ efficiency by offering a ready to use product but more importantly help to reduce medication errors. Prefilled syringes are practical, reliable and secure.

MedXL Europe BV is a Dutch based medical device company with a key focus on the area of Vascular Access and automated systems for the prepration of medication in syringes. Providing market leading solutions for both central venous catheter and AV fistula access. We are committed to helping patients and healthcare professionals to maintain vascular access patency whilst simultaneously reducing catheter related blood stream infections (CRBSI).

Our team of experts have extensive experience of providing catheter care and offering solutions for a wide array of access issues in Europe and Africa.

MicroBioSensor is a medical device company that manufactures point-of-care infection diagnostics. Our lead product, QuickCheck, provides a rapid white blood cell count in peritoneal dialysis effluent, simplifying diagnosis and infection management for PD patients.

We are here.
We are ready.
We are Mozarc Medical.

Supported by an investment from Medtronic, Inc. and DaVita, Inc., we are based on both companies’ leadership and expertise to develop transformative kidney health technologies. Because patients, caregivers, clinicians- they all deserve better.

Home

As the first major Canadian company to enter the hemodialysis market, NephroCan is a leading provider of a fully integrated product and services offering for End Stage Renal Disease (ESRD) patients. Comprised of nephrologists, nurses, engineers, quality management professionals, and a vast R&D team, we offer reliable, cost-effective products to patients worldwide.

NephroCan was founded on the principle that every hemodialysis patient deserves to have the best quality treatment built around their specific needs, irrespective of circumstance or location. With a mission to better the quality of life for ESRD patients, we believe that hemodialysis care should be equal, accessible, and affordable.

Nephrokit is an entity of Gergonne Group whose main objective is to provide to dialysis caregivers solutions that enable the rationalization and standardization of techniques for securing needles and catheters for hemodialysis and reducing bleeding during and after dialysis session.

———-

Nephrokit est une entité du groupe Gergonne qui a pour principal objectif de fournir au professionnels de la dialyse des solutions permettant de rationnaliser et de standardiser les techniques de sécurisation des aiguilles et des cathéters pour l’hémodialyse mais aussi de réduire les temps de saignements pendant et après la séance de dialyse.

Nephrolyx offers a precise and rapid measurement of the kidney function (true GFR). We provide hospitals and laboratories with an In-Vitro Diagnostic Test and a digital platform to measure the true GFR within only a few hours. For the first time, physicians can detect renal diseases using the highest accuracy of GFR measurement and adapt an optimal treatment plan for patients. Especially nephrology, oncology, transplantation, and ICU patients can benefit from rapid and precise diagnostics.

The Nephrolyx IVDx is indicated for the in-vitro quantitative determination of serum iohexol concentration and calculation of the glomerular filtration rate (GFR). The principle of the test is based on Ultra-High-Performance-Liquid Chromatography using Ultra-Violet light.

Proprietary technology from Nephrolyx helps to improve treatment success for kidney patients. Given its low component cost, the Nephrolyx IVDx can also significantly enhance the performance of the entire healthcare system.

NextKidney’s mission is to develop and commercialize the Neokidney home hemodialysis device. Placing the patient and his quality of life at the center of its approach, the company uses innovative technologies to offer a safe, practical, and easy-to-use solution as quickly and widely as possible throughout the world.

Optimising patient care is at the core of our ethos.

NIKKISO, a pioneer in Renal Replacement Therapies, strives to advance complex medical technologies that optimise patient care in End-stage Renal and Critical Care areas. Through our commitment to improving clinical efficiency and patient QoL, Nikkiso has built a global reputation for unparalleled quality and innovation. This is mirrored by technical and medical solutions integrated in NIKKISO’s medical and health care devices.

DBB-EXA series, our dialysis machines for online hemodialysis (online HD) and online hemodiafiltration (online HDF), provide high-end usability and a wide range of value-oriented solutions and features, achieved by integrating decades of NIKKISO’s expertise in Renal Replacement Therapies.
DBB-EXA ES is today the first launched single pump dialysis machine that performs online priming, online bolus and online wash back in HD treatments.
The integrated automatisms of the DBB-EXA (e.g. automatic priming, treatment start and wash back), and its proven reliability, contribute to the noticeable success of the DBB-EXA in Western Europe countries, underlined by growing market shares and customers satisfaction.

PureADJUST, our compact hemoperfusion pump, offers a broad touch-screen for a clear visibility, a smart layout to favor easy blood circuit setup and an on-screen navigation to support simple operation. Further, frequently used Direct Hemoperfusion Adsorbers can be pre-registered to enhance versatility.

Aquarius System with Aquarius+ software uses accuracy and simplicity to deliver CRRT, hemoperfusion or therapeutic plasma exchange therapies regardless of anticoagulant needs of the patient with a single line set.

Nipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 36.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.

Nipro Renal Care is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment. In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.

Live Longer. Live Better.
Caring to improve patient outcomes and quality of life for all!

Nova Biomedical is a world leader in point of care and critical care in vitro diagnostics. We offer products with a renal function panel, that can be used either within or outside the hospital setting.
• Stat Profile Prime Plus® blood gas critical care analyzer with a kidney function panel. Using maintenance-free sensors, the system offers a comprehensive 22-test blood gas menu including tests for iMg, Urea, Creatinine, estimated Plasma Volume (ePV) and Co-oximetry.
• StatSensor® Creatinine measures capillary whole blood creatinine and calculates eGFR to enable a rapid assessment of renal function prior to the administration of nephrotoxic drugs in areas such as Accident & Emergency, Radiology or Oncology.
• NovaMax Pro eGFR® is an important new tool to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The Nova Max Pro measures blood creatinine and calculates estimated glomerular filtration rate (eGFR), two important indicators of overall kidney function, from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds.
• Allegro®, a compact, capillary blood analyser offering a kidney function panel designed for use in primary care or hospital clinics. The system can measure HbA1c, Lipids, Glucose, Creatinine, CRP and PT/INR from capillary whole blood, plus Urine Albumin and Creatinine; with all tests using disposable cartridges and test strips.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and other related indications.

SCIARC is characterised by innovative solutions that are committed to the rapid changes in
medicine at the beginning of the 21st century. The company stands for competent knowledge
transfer in medicine, which is expressed in the areas of medical education – CME and webcasts
as well as medical writing and consulting. We also analyse complex research results with a view
to clinical benefit and build the bridge to the correct implementation of scientific findings in
clinics and medical practice.

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy:
“Otsuka-people creating new products for better health worldwide.” Otsuka researches,
develops, manufactures and markets innovative products, focusing on pharmaceutical
products to meet unmet medical needs and nutraceutical products for the maintenance of
everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental
health and also has research programs in several under-addressed diseases including
tuberculosis, a significant global public health issue.
Otsuka employs around 550 people in Europe and focuses on psychiatric and
neurologic disorders, infectious disease, nephrology, oncology, and digital medicines.
Otsuka Italy is an affiliate of Otsuka Pharmaceutical Europe Ltd. which is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan.
The Otsuka group of companies employed 47,000 people worldwide with consolidated sales of approximately €12.4 billion and a spend of €1.67 billion on research and development in 2022. For further information on Otsuka in Europe, please visit www.otsuka-europe.com.

Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has approximately 500 employees.

Leader in home hemodialysis, Physidia is a French company specialized in developing, manufacturing and commercializing an innovative equipment and disposables for delivering frequent home hemodialysis treatment.
Physidia’s innovations are based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a performing treatment in total autonomy.

Created by an expert team, Physidia’s S³ monitor has been specifically developed to respond to the needs of simplicity and safety of ESRD patients in home hemodialysis. The Physidia S³ monitor offers the treatment of renal failure with daily dialysis sessions of 2 to 3 hours 5 to 6 times a week.
Daily hemodialysis is recognized today as the most physiological therapy for the patient experiencing renal failure as this therapy provides outcomes close to natural kidney functioning.

Physidia is present today in 16 countries, operating directly in France and through distributor partners in the rest of Europe and middle east. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient.

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense Alarm System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

Reliant Glycosciences, LLC is a biotechnology company that focuses on developing diagnostic and prognostic tools for patients with IgA nephropathy. Reliant was spun-out in 2016 from UAB. Reliant’s goal is to develop marketable assays for these IgAN-specific biomarkers so that they can be available to the IgAN research community as well as pharmaceutical companies interested in developing treatments for IgAN. Reliant’s goal is to have an impact on the disease itself and the treatment.

Riva Mühendislik Su Arıtma Sistemleri San. ve Tic. Ltd. Şti. (Riva Engineering) was officially established in 2006 focusing on water treatment systems in especially medical fields. Our company, which has been providing industrial water treatment systems services since 2006, our company has been actively serving in the medical sector with turnkey solutions, 24/7 technical service and after-sales support. In 2018, Riva Mühendislik became the only domestic manufacturer of CE certified hemodialysis water treatment systems branded RİVAMED in accordance with medical devices directive (MDD) 93/42/EEC.
We manufacture RİVAMED HD-RO and RİVAMED RM hemodialysis water treatment systems with taking into account the up-to-date technology and ease of use, also comply with the 93/42/EEC medical devices directive. Our systems are capable of producing pure water for different capacities with maximum water contaminant values in accordance with European Pharmacopoeia and Turkey Ministry of Health guidelines for hemodialysis. In addition to the fixed water system for different capacities for public hospitals, city hospitals, private hospitals and dialysis centers feeding up to 60 hemodialysis machines, our portable water treatment systems are used in intensive care units (ICUs). We also offer a larger capacity water system according to the needs of the projects.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Rontis, a Switzerland based multinational healthcare corporation, was established in 1986 by a group of leading professionals with lengthy experience in the wider healthcare sector and a vision to provide the most innovative & trustworthy solutions in the market, aiming to become an international leader in the global healthcare industry. We have a history in R&D & manufacturing of Medical Devices, Pharmaceuticals and Dialysis Services.
Medical Devices: we produce disposables for Nephrology, Liquid Administration, as well as products for Interventional Cardiology & Radiology.
Pharmaceuticals: Rontis has a vertically integrated manufacturing system that is supported by the R&D division.
We also provide Original Equipment Manufacturer (OEM) and custom-made solutions.
Website: www.rontis.com

Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.
Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Science Collected is a medical education agency that provides educational grant funded accredited-CME (Continuing Medical Education), accredited-CPD (Continuing Professional Development) and IME (Independent Medical Education) programmes for healthcare professionals.

Collected Group agencies. Science Collected is part of Collected Group, a forward-thinking healthcare communication company comprised of agencies that specialise in providing innovative and immersive omniverse centred engagement experiences for healthcare audiences.

At STADA, our purpose of Caring for People’s Health as a Trusted Partner means supplying a broad portfolio of high-quality pharmaceuticals across three business units. Specialty Pharmaceuticals provides tailored treatment options for specific and unmet patient needs, including orphan drugs for rare diseases and six marketed biosimilars, in therapeutic categories including nephrology, neurology, oncology, immunology and ophthalmology. Generics enable access to well-proven treatments as Europe’s fourth-largest supplier. A broad range of Consumer Healthcare brands provides patients and consumers with appealing options to manage their own health.
Headquartered in Bad Vilbel, Germany, STADA sells its products in approximately 120 countries worldwide. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. Sobi headquarters are located in Stockholm, Sweden.

Takeda is a patient-focused, global biopharmaceutical company. We continue to seek innovations and personalized care in immunology, including potential management options to help address the unmet medical needs of patients with IgA Nephropathy. More information can be found on www.clinicaltrials.takeda.com.

In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.

Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority.

Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.

In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.

Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority.

Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.

At Travere Therapeutics, we are in rare for life. We come together everyday to help patients, families, and caregivers as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop, and deliver life-changing therapies. We continuously seek to understand the diverse perspectives of rare patients and courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It invests in cutting-edge science and innovation, including small molecules and cell and genetic therapies, to tackle serious disease like cystic fibrosis, sickle cell disease, alpha-1 antitrypsin deficiency, beta thalassemia, type 1 diabetes, APOL1-mediated kidney disease and pain.

WEGO Blood Purification Group was established in 2004 and focusing on the field of blood purification. Around 5100 employees are serving more than 5000 customers worldwide. It has gradually become a outcome international industrial group with first-class technology and quality.

WEGO Blood Purification Group owns 14 subsidiaries and joins force together with two major international medical group companies, Terumo and Nikkiso, to provide hemodialysis, peritoneal dialysis and
hemodialysis service business. WEGO Blood Purification Group has achieved the coverage of the whole industrial chain of products and services related to blood purification. We are devoted to providing top-quality products and treatment to our patients worldwide.

WEGO Blood Purification Group belongs to WEGO Group which is one of the top 500 enterprises in China and employing more than 30,000 people worldwide. WEGO Group has more than 80 subsidiaries which covers 12 industries in Blood Purification, Orthopedics, Medical Equipment, Pharmaceuticals, Cardiac Consumables, Medical Business and Surgical Robotics etc.

We are Weltenmacher. And we strive to make education better by combining VR and AI. We develop VR based educational applications that are used to support trainees, but also skilled employees as well as patients with motivating and safe learning.

Step into a world of immersive learning at our booth in the Innovation Hub and witness how virtual reality is reshaping healthcare education, delivering realistic simulations and empowering professionals to excel in their skills.

/

American Society of Onconephrology was stablished in 2021 to promote research, clinical activities, and education related to onconephrology. More specifically, the primary objectives of this society is to further the investigation of onconephrology and reach a better understanding of the basic mechanisms involved as follows:
1. By informal group discussion of material that is of cross disciplinary interest as it pertains to care of patients with kidney disease and cancer.
2. By exchange of ideas pertaining to clinical experiences and experimental research
3. By consideration of problems encountered in onco-nephrology research.
4. By the promotion of good fellowship and mutual trust among members of this organization.
5. By fostering education and identifying gaps in knowledge as it pertains to onco-nephrology.

Join us in the beautiful city of Bruges, Belgium, from 27-30 November 2023 for the 16th EuroPD meeting.
This year’s programme will expand on the Home Haemodialysis component of the meeting and will have a strong focus on the need to grow Home Dialysis Therapies throughout Europe.  The pre-congress educational courses will include a full day of presentations in French, and the main programme features high quality speakers on topics ranging from basic science and the
findings of the EU funded IMPROVE-PD programme, through qualitative research describing centre culture and modality selection, to life participation and technological innovations. See you in Bruges!

The European Kidney Patients’ Federation (EKPF) is a non-profit organization that advocates for kidney patients in Europe.
Representing over 75 million people affected by kidney conditions, the EKPF brings together 27 national kidney patient federations from 26 different countries in Europe. The organization is dedicated to raising awareness of kidney disease at the European level and promoting prevention and early detection.
Through its work, the EKPF aims to improve the well-being, treatment, social security, and living conditions of all kidney patients and their families and carers. The organization also strives to increase cooperation and information exchange with other organizations and institutions involved in kidney diseases, and to encourage organ donation and transplantation.

The European Society for Paediatric Nephrology (ESPN) was founded in 1967 with the goal of diffusing knowledge and improving the treatment of children with kidney diseases. ESPN brings together clinical professionals and researchers that operate in the field of Paediatric Nephrology throughout Europe. ESPN has approximately 700 active members. Our Society has multiple activities including the annual congress, collaborative research projects, teaching courses, workshops, webinars, clinical practice guidelines, a three-year curriculum in Paediatric Nephrology, and a EU-certified board examination in Paediatric Nephrology among others. Within the ESPN, six working groups operate providing focused research and educational opportunities.
The ESPN council includes the President, the Assistant President, a Treasurer (executive councilors), and eight other councilors. Ex officio council members and chair positions include the chair of the ESPN/ERA registry, the President of the annual ESPN congress, chairs of standing and special committees or task forces, chairs of the ESPN working groups, and the chair, vice-chair, and elected representative of the Young Paediatric Nephrology Network (YPNN).
ESPN is the official European partner of the International Pediatric Nephrology Association (IPNA) (https://theipna.org) and is closely associated by mutual agreement with the European Renal Association (ERA) (https://www.era-online.org).

Become a member

ERKNet is the European Reference Network for Rare Kidney Diseases, a consortium of 72 expert pediatric and adult nephrology centers in 24 European countries providing healthcare to more than 70,000 patients with rare disorders of the kidneys. The ERKNet partners offer top quality multidisciplinary healthcare for a wide range of rare kidney disorders. They uniformly apply clinical guidelines and pathways according tolatest medical knowledge and strictly monitor the quality and outcomes of therapy across the Network.
ERKNet offers virtual consultation services to physicians throughout Europe who need advice for challenging cases with a rare kidney disease.
ERKNet is dedicated to improve knowledge about rare kidney diseases among patients and healthcare professionals. We disseminate disease information via this website and by multiple education and training activities.
ERKNet works closely with European patient advocates (ePAGs) and different renal patient communities and organizations.
ERKNet actively supports clinical research to improve diagnosis and risk prediction and advance the development of new therapies for patients with rare kidney disorders.

The 21st Congress of the International Society of Renal Nutrition & Metabolism (ICRNM), will be held from 28th -31st August 2024, at Hyderabad, India.

The International Society for Peritoneal Dialysis works to increase the global uptake, promote quality practice, and achieve optimal outcomes of peritoneal dialysis through enhanced advocacy, research, and education, in order to improve the health and well-being of people living with end-stage kidney disease or suffering from acute kidney injury. Our members are doctors, nurses and kidney health professionals who are PD enthusiasts and work together for advancing PD worldwide.

The mission of the JSN is to aid in the practice and study of Nephrology. In order to achieve this the JSN conducts a range of activities. These include holding regular meetings as a forum for the diffusion of information, producing regular journals, coordinating clinical research, promoting cooperation with related societies in Japan and internationally, as well as providing recognition to those who have made significant contributions in the field of Nephrology.

Journal of Kidney Care (JKC) is the essential bi monthly peer-reviewed publication for all members of the multidisciplinary renal team. It covers several clinical areas of renal medicine, such as dialysis, transplantation, diabetes, anaemia, pharmacy and nutrition. JKC’s content is aimed at doctors, nurses, healthcare assistants, dietitians, pharmacists, physiotherapists, paediatric specialists, clinical technologists, social workers, vascular access specialists and transplant surgeons and coordinators specialising in kidney care.

Oxford University Press advances knowledge and learning. We are a department of the University of Oxford and share the objective of excellence in research, scholarship, and education by publishing worldwide. Oxford University Press is the publisher of the ERA’s official journals, Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ). NDT and CKJ are leading journals in the field of nephrology research, and CKJ is fully Open Access.

PKD International is the global alliance of patient organisations supporting everyone affected by polycystic kidney disease. Our mission is to improve the lives of an estimated 12.5 million affected by PKD worldwide, and their families and care-givers. We do this by uniting patients, families, scientists, and healthcare professionals committed to ending PKD. PKD International is a non-profit, non-governmental association (NGO) based in Geneva, Switzerland. We will be joined at the Congress by colleagues from AIRP (PKD Italy) and FEDERG (European Federation for Rare/Inherited Kidney Diseases). PKD patient groups, individuals and clinicians, scientists and other healthcare professionals worldwide are invited to join PKD
International. Follow us on Twitter
@pkd_int and https://www.linkedin.com/company/pkd-international

Karger Publishers is a worldwide publisher of scientific and medical content based in Basel, Switzerland. It is independent and family-led in the fourth generation by Chairwoman and Publisher Gabriella Karger. Connecting and advancing health sciences since 1890, Karger has been continuously evolving, keeping pace with the current developments and shifts in research and publishing. The publishing house is dedicated to serving the information needs of the scientific community, clinicians, and patients with publications of high-quality content and services in health sciences. Karger Publishers has 230 employees and is present in 15 countries around the globe.
For more information, please visit: karger.com

The UK Kidney Association (UKKA) is the leading professional body for the UK kidney community, dedicated to improving the lives of people living with kidney disease by supporting professionals and shaping the delivery of kidney care. We have over 1,600 doctors, scientists and multi-professional team members.
For 73 years, the Renal Association, now the UKKA, has been transforminghow kidney care and research are delivered in the UK and beyond. The work we deliver and fund to support our members and people living with kidney disease is wide-ranging and includes:

• The UK Renal Registry
• British Association for Paediatric Nephrology
• UK Renal Pharmacy Group
• Kidney Quality Improvement Partnership (KQuIP)
• The UK Specialty Renal Trainees
• Paediatric Nephrology Nurses Group
• Rare Renal and the National Registry of Rare Kidney Diseases (RaDaR)
• Renal Social Work Group
• Renal Psychological Therapist Group

The UKKA also hosts UK Kidney Week, the largest UK event for kidney professionals.

Tweets by UKKidney